A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms KEYNOTE-348
- Sponsors Amgen
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 Planned End Date changed from 7 Jan 2025 to 24 Jan 2025.
- 05 Mar 2018 Planned primary completion date changed from 23 Mar 2021 to 22 Mar 2021.